F
Fanny Piette
Researcher at Université catholique de Louvain
Publications - 19
Citations - 4224
Fanny Piette is an academic researcher from Université catholique de Louvain. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 13, co-authored 19 publications receiving 3845 citations. Previous affiliations of Fanny Piette include Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Sherene Loi,Nicolas Sirtaine,Fanny Piette,Roberto Salgado,Giuseppe Viale,Françoise Van Eenoo,Ghizlane Rouas,Prudence A. Francis,John Crown,Erika Hitre,Evandro de Azambuja,E. Quinaux,Angelo Di Leo,Stefan Michiels,Martine Piccart,Christos Sotiriou +15 more
TL;DR: In node-positive, ER-negative/HER2-negative BC, increasing lymphocytic infiltration was associated with excellent prognosis and the data also support the evaluation of immunotherapeutic approaches in selected BC subtypes.
Journal ArticleDOI
Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer
Marc Buyse,Sherene Loi,Laura J. van't Veer,Giuseppe Viale,Mauro Delorenzi,Annuska M. Glas,Mahasti Saghatchian d'Assignies,Jonas Bergh,Rosette Lidereau,Paul Ellis,Adrian L. Harris,Jan Bogaerts,Patrick Therasse,Arno Floore,Mohamed Amakrane,Fanny Piette,Emiel J. Th. Rutgers,Christos Sotiriou,Fatima Cardoso,Martine Piccart +19 more
TL;DR: The 70-gene signature adds independent prognostic information to clinicopathologic risk assessment for patients with early breast cancer and outperformed the clinicopathological risk assessment in predicting all endpoints.
Journal ArticleDOI
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,
Christine Desmedt,Fanny Piette,Sherene Loi,Yixin Wang,Françoise Lallemand,Benjamin Haibe-Kains,Giuseppe Viale,Mauro Delorenzi,Yi Zhang,Mahasti Saghatchian d'Assignies,Jonas Bergh,Rosette Lidereau,Paul Ellis,Adrian L. Harris,Jan Klijn,John A. Foekens,Fatima Cardoso,Martine Piccart,Marc Buyse,Christos Sotiriou +19 more
TL;DR: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases.
Journal ArticleDOI
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Angelo Di Leo,Christine Desmedt,John M. S. Bartlett,Fanny Piette,Bent Ejlertsen,Kathleen I. Pritchard,Denis Larsimont,Christopher J. Poole,Jorma Isola,Helena M. Earl,Henning T. Mouridsen,Frances P. O'Malley,Fatima Cardoso,Minna Tanner,Alison F. Munro,Chris J. Twelves,Christos Sotiriou,Lois E. Shepherd,David Cameron,Martine Piccart,Marc Buyse +20 more
TL;DR: Although HER2 amplification and combined TOP2A amplification and deletion may have some value in the prediction of responsiveness to anthracycline-based chemotherapy, the findings do not support the use of anthrACYclines only in patients with HER2-amplified or TOP1A-aberrated tumours.
Journal ArticleDOI
Comparison of prognostic gene expression signatures for breast cancer
Benjamin Haibe-Kains,Christine Desmedt,Fanny Piette,Marc Buyse,Fatima Cardoso,Laura J. van't Veer,Martine Piccart,Gianluca Bontempi,Christos Sotiriou +8 more
TL;DR: The three signatures had similar capabilities of predicting DMFS and added significant prognostic information to that provided by the classical parameters, adding to the growing evidence that these prognostic signatures are of clinical relevance.